title: Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: results with ALK-11 antibody in 327 untreated patients.
abstract: The t(2;5)(p23;q35) or other rare chromosomal abnormalities involving 2p23 upregulate the ALK gene, which is not expressed in normal lymphocytes. Thus, detection of ALK protein is presumptive evidence of these 2p23 abnormalities. The t(2;5) and ALK immunoreactivity are common in anaplastic large cell lymphoma of T/null-cell lineage. However, a small subset of cases of Hodgkin's disease (HD) have been reported to either carry the t(2;5) or express ALK. In this study, we have immunohistochemically evaluated 327 cases of HD with the ALK-11 antibody. ALK-11 is a well characterized polyclonal antibody raised against an intracellular portion of the ALK protein. We detected ALK-11 immunoreactivity in 8 (2.4%) cases of HD. We further studied these positive cases with ALK-1 monoclonal antibody, which reacts with an intracellular portion of ALK, similar to ALK-11. All 8 ALK-11 positive cases were negative for ALK-1. These results indicate that rare cases of HD may react with ALK-11 antibody, similar to previous reports by others using different polyclonal anti-ALK antibodies. However, the absence of ALK-1 expression in these HD cases suggests that ALK protein is not truly present and that polyclonal anti-ALK antibodies may rarely yield non-specific cross reactivity. These results further support the use of anti-ALK antibodies in the differential diagnosis of HD from ALCL.
authors.affiliation: Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: M
authors.initials: M
authors.lastname: Herling
authors.forename: G Z
authors.initials: GZ
authors.lastname: Rassidakis
authors.forename: S
authors.initials: S
authors.lastname: Viviani
authors.forename: V
authors.initials: V
authors.lastname: Bonfante
authors.forename: R
authors.initials: R
authors.lastname: Giardini
authors.forename: M
authors.initials: M
authors.lastname: Gianni
authors.forename: S W
authors.initials: SW
authors.lastname: Morris
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: L J
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: A H
authors.initials: AH
authors.lastname: Sarris
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077548:Anaplastic Lymphoma Kinase; D000906:Antibodies; D002648:Child; D002675:Child, Preschool; D003429:Cross Reactions; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005189:False Positive Reactions; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000201:enzymology*; D006801:Humans; D007150:Immunohistochemistry; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000201:enzymology; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000032:analysis* / Q000276:immunology; D020794:Receptor Protein-Tyrosine Kinases; D014407:Tumor Cells, Cultured
chemical_list: D000906:Antibodies; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases